Drug Trial Radar · NCT06501573
A Study of SGB-9768 in Adult Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jul 18, 2024
Primary completion
May 7, 2026
Study completion May 7, 2026
Sponsor
- Lead sponsor
- Suzhou Sanegene Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled single ascending dose study of SGB-9768 in healthy volunteers. The purpose is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SGB-9768.
Conditions
- Healthy Volunteer
Interventions
SGB-9768Drug
SGB-9768 for sc injection
PlaceboOther
sterile normal saline (0.9% NaCl) for sc injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of SGB-9768Time frame: 169 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.